Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab for Primary Membranous Nephropathy (ORION)
NCT05050214Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Feb 2022
- Primary completion
- Feb 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in membranous nephropathy (MN), sponsored by Mario Negri Institute for Pharmacological Research. Started Feb 2022; status: completed.
02
Drugs
obinutuzumab
03
Conditions
membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT05050214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050214.